Blog | Veristat, The Science-First CRO

Gain the latest insights and trends in clinical trials, patient recruitment, data analysis, adaptive design, regulatory submissions and approvals.

Sign Up Today

4 min read

Regulatory Guidance Monthly Review - February 2024

Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA) that are pertinent to the governance of clinical trials and drug, biologic, or medical device development...

READ MORE

2 min read

Navigating the IND Submission Labyrinth: A Veristat Success Story

At Veristat, we pride ourselves on transforming challenges into triumphs, particularly in the complex pharmaceutical and biotech development world. Our recent collaboration with a small-sized biotech company targeting cancers of the reproductive system...

READ MORE

2 min read

Regulatory Guidance Monthly Review - January 2024

Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA) that are pertinent to the governance of clinical trials and drug, biologic, or medical device development...

READ MORE

1 min read

Veristat Joined the Battle to Fight Rare Cancers for the Tenth Year Running with Cycle for Survival 2024

We did it again! A Successful Cycle for Survival Ride Raising Over $90K To Support Rare Cancer Research

READ MORE

1 min read

Pursuing Breakthrough Therapies for Rare Metabolic Diseases: Veristat's Role in a Landmark Clinical Study

At Veristat, we recently embarked on an ambitious journey alongside a biotech organization specializing in gene therapies for metabolic diseases. Our engagement entailed supporting their Phase I/II clinical study for a rare human genetic lysosomal...

READ MORE

3 min read

Regulatory Guidance Monthly Review - December 2023

Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA) that are pertinent to the governance of clinical trials and drug, biologic, or medical device development...

READ MORE

1 min read

Elevating CNS Drug Development: Veristat’s Agile Approach in Medical Writing and Project Management

Precision and efficiency are key in the intricate world of CNS drug development. Veristat's recent collaboration with a clinical-stage biopharmaceutical company showcases an agile medical writing and project management approach, revolutionizing the...

READ MORE

2 min read

FDA CDER’s Accelerating Rare disease Cures (ARC) Program

In 2022, the FDA’s Center for Drug Evaluation and Research (CDER) launched the Accelerating Rare disease Cures (ARC) Program to help bridge the gap between the urgent needs of patients and the complexities of rare disease drug development.

ARC’s mission...

READ MORE

3 min read

Regulatory Guidance Monthly Review - November 2023

Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA) that are pertinent to the governance of clinical trials and drug, biologic, or medical device development...

READ MORE